Gregory G Schwartz

Summary

Country: USA

Publications

  1. ncbi Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial
    G G Schwartz
    Cardiology Section 111B, Denver VA Medical Center, 1055 Clermont St, Denver, CO 80220, USA
    JAMA 285:1711-8. 2001
  2. ncbi Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial
    Gregory G Schwartz
    Cardiology Section, VA Medical Center, Denver, Colorado 80220, USA
    Diabetes Care 28:2508-13. 2005
  3. ncbi The case for intensive statin therapy after acute coronary syndromes
    Gregory G Schwartz
    Cardiology Section, Veterans Affairs Medical Center, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Am J Cardiol 96:45F-53F. 2005
  4. ncbi Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial
    Gregory G Schwartz
    University of Colorado, Denver VA Medical Center, Denver, Colo 80220, USA
    Am Heart J 148:e4. 2004
  5. ncbi Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes
    Gregory G Schwartz
    Veterans Administration Medical Center and University of Colorado Health Sciences Center, Denver, Colorado 80220, USA
    Am J Cardiol 92:1109-12. 2003
  6. ncbi Lipid lowering in acute coronary syndromes: new evidence, new questions
    Gregory G Schwartz
    Cardiology Section, 111B, Denver VA Medical Center, 1055 Clermont Street, Denver, CO 80220, USA
    Curr Atheroscler Rep 4:1-3. 2002
  7. ncbi Effects of dalcetrapib in patients with a recent acute coronary syndrome
    Gregory G Schwartz
    Cardiology Section, Veterans Affairs Medical Center and University of Colorado School of Medicine, Denver, 80220, USA
    N Engl J Med 367:2089-99. 2012
  8. ncbi Impaired contractile recovery after low-flow myocardial ischemia in a porcine model of metabolic syndrome
    Janice V Huang
    Cardiology Section, Veterans Affairs Medical Center, Denver, CO 80220, USA
    Am J Physiol Heart Circ Physiol 304:H861-73. 2013
  9. ncbi Calpain inhibition preserves talin and attenuates right heart failure in acute pulmonary hypertension
    HASAN A AHMAD
    Cardiology Section, Veterans Affairs Medical Center, 1055 Clermont Street, Cardiology 111B, Denver, CO 80220, USA
    Am J Respir Cell Mol Biol 47:379-86. 2012
  10. ncbi High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial
    Gregory G Schwartz
    VA Medical Center, University of Colorado, Denver, USA
    Am Heart J 161:993-9. 2011

Detail Information

Publications29

  1. ncbi Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial
    G G Schwartz
    Cardiology Section 111B, Denver VA Medical Center, 1055 Clermont St, Denver, CO 80220, USA
    JAMA 285:1711-8. 2001
    ....
  2. ncbi Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial
    Gregory G Schwartz
    Cardiology Section, VA Medical Center, Denver, Colorado 80220, USA
    Diabetes Care 28:2508-13. 2005
    ..We examined relations between characteristics of the metabolic syndrome, early cardiovascular risk, and effect of early, intensive statin therapy after acute coronary syndrome...
  3. ncbi The case for intensive statin therapy after acute coronary syndromes
    Gregory G Schwartz
    Cardiology Section, Veterans Affairs Medical Center, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Am J Cardiol 96:45F-53F. 2005
    ..Moreover, evidence suggests that anti-inflammatory effects of high-intensity statin treatment are associated with clinical benefit...
  4. ncbi Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial
    Gregory G Schwartz
    University of Colorado, Denver VA Medical Center, Denver, Colo 80220, USA
    Am Heart J 148:e4. 2004
    ..This double-blind, multicenter, randomized trial compared rosuvastatin and atorvastatin for reducing low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia and a high risk of coronary heart disease...
  5. ncbi Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes
    Gregory G Schwartz
    Veterans Administration Medical Center and University of Colorado Health Sciences Center, Denver, Colorado 80220, USA
    Am J Cardiol 92:1109-12. 2003
    ..The net incremental cost of atorvastatin treatment was 157 dollars/patient with a cost-effectiveness ratio of 4,086 dollars/event avoided...
  6. ncbi Lipid lowering in acute coronary syndromes: new evidence, new questions
    Gregory G Schwartz
    Cardiology Section, 111B, Denver VA Medical Center, 1055 Clermont Street, Denver, CO 80220, USA
    Curr Atheroscler Rep 4:1-3. 2002
  7. ncbi Effects of dalcetrapib in patients with a recent acute coronary syndrome
    Gregory G Schwartz
    Cardiology Section, Veterans Affairs Medical Center and University of Colorado School of Medicine, Denver, 80220, USA
    N Engl J Med 367:2089-99. 2012
    ..Inhibition of cholesteryl ester transfer protein (CETP) raises HDL cholesterol levels and might therefore improve cardiovascular outcomes...
  8. ncbi Impaired contractile recovery after low-flow myocardial ischemia in a porcine model of metabolic syndrome
    Janice V Huang
    Cardiology Section, Veterans Affairs Medical Center, Denver, CO 80220, USA
    Am J Physiol Heart Circ Physiol 304:H861-73. 2013
    ..Contributory mechanisms may include remodeling of cardiolipin, abnormal activation of Akt, and excessive utilization of fatty acid substrates...
  9. ncbi Calpain inhibition preserves talin and attenuates right heart failure in acute pulmonary hypertension
    HASAN A AHMAD
    Cardiology Section, Veterans Affairs Medical Center, 1055 Clermont Street, Cardiology 111B, Denver, CO 80220, USA
    Am J Respir Cell Mol Biol 47:379-86. 2012
    ..Calpain inhibition preserves the abundance and organization of talin and RV function. Calpain inhibition may offer clinical utility in treating acute cor pulmonale...
  10. ncbi High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial
    Gregory G Schwartz
    VA Medical Center, University of Colorado, Denver, USA
    Am Heart J 161:993-9. 2011
    ..We tested the hypothesis that long-term treatment with high-dose atorvastatin reduces occurrence of AF in patients with prior stroke or transient ischemic attack...
  11. ncbi High-density lipoprotein cholesterol as a risk factor and target of therapy after acute coronary syndrome
    Gregory G Schwartz
    CardiologySection 111B, Veterans Affairs Medical Center, 1055 Clermont Street, Denver, Colorado 80220, USA
    Am J Cardiol 104:46E-51E. 2009
    ..Clinical trials are in progress to test the hypothesis that strategies to raise levels of HDL cholesterol will reduce risk after ACS...
  12. ncbi PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty
    Janice V Huang
    Cardiology Section, Denver VA Medical Center, US Department of Veterans Affairs, Denver, CO, USA
    J Lipid Res 53:1738-54. 2012
    ..This review addresses these issues from a clinician's perspective and highlights several ongoing clinical trials that may help to clarify the therapeutic role of PPAR-γ activators in cardiovascular disease...
  13. ncbi Thiazolidinedione drugs promote onset, alter characteristics, and increase mortality of ischemic ventricular fibrillation in pigs
    Mohammad Sarraf
    Cardiology Section, VA Medical Center and University of Colorado, Denver, CO, USA
    Cardiovasc Drugs Ther 26:195-204. 2012
    ....
  14. ncbi Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome
    Gregory G Schwartz
    VA Medical Center and University of Colorado, Denver, CO 80220, USA
    Am Heart J 158:896-901.e3. 2009
    ..Dal-OUTCOMES is a multicenter, randomized, double-blind, placebo-controlled trial designed to test the hypothesis that CETP inhibition with dalcetrapib reduces cardiovascular morbidity and mortality in patients with recent ACS...
  15. ncbi New horizons for cholesterol ester transfer protein inhibitors
    Gregory G Schwartz
    VA Medical Center and University of Colorado, Denver, CO 80220, USA
    Curr Atheroscler Rep 14:41-8. 2012
    ..Two large cardiovascular outcomes trials, one with anacetrapib and one with dalcetrapib, should provide a conclusive test of the hypothesis that inhibition of CETP decreases cardiovascular risk...
  16. ncbi Multiple abnormalities of myocardial insulin signaling in a porcine model of diet-induced obesity
    Jenny Lee
    Veterans Affairs Medical Center, University of Colorado, Denver, Colorado, USA
    Am J Physiol Heart Circ Physiol 298:H310-9. 2010
    ....
  17. ncbi Lipid management after acute coronary syndrome
    Gregory G Schwartz
    VA Medical Center and University of Colorado Health Sciences Center, Denver, Colorado 80220, USA
    Curr Opin Lipidol 18:626-32. 2007
    ..Interventions targeting atherogenic lipoproteins may favorably modify this risk...
  18. ncbi Deleterious effects of acute treatment with a peroxisome proliferator-activated receptor-gamma activator in myocardial ischemia and reperfusion in pigs
    Ya Xu
    VA Medical Center and University of Colorado Health Sciences Center, Denver, CO, USA
    Diabetes 52:1187-94. 2003
    ..Acute treatment with troglitazone increases susceptibility to ventricular fibrillation during myocardial ischemia and reperfusion. Whether thiazolidinediones have proarrhythmic potential in clinical use requires further investigation...
  19. ncbi Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study
    Scott Kinlay
    Cardiovascular Division, Veterans Affairs Boston Healthcare System, West Roxbury, Mass, USA
    Arterioscler Thromb Vasc Biol 28:142-7. 2008
    ..We measured markers of inflammation in the MIRACL study, a randomized trial of atorvastatin versus placebo in acute coronary syndromes, to assess the relationship of inflammation to stroke...
  20. ncbi Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy
    David D Waters
    Division of Cardiology, San Francisco General Hospital, and the University of California, San Francisco School of Medicine, San Francisco, Calif 94110, USA
    Circulation 106:1690-5. 2002
    ..4% in the placebo group to 14.8% in the atorvastatin group over the 16 weeks of the trial (P=0.048)...
  21. ncbi Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study
    Scott Kinlay
    Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass 02115, USA
    Circulation 110:386-91. 2004
    ..Early statin therapy after acute coronary syndromes counters the risk associated with elevated sCD40L...
  22. ncbi High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial
    Sotirios Tsimikas
    Vascular Medicine Program, Department of Medicine, University of California San Diego, 9500 Gilman Dr, BSB 1080, La Jolla, CA 92093 0682, USA
    Circulation 110:1406-12. 2004
    ..This study evaluated the impact of atorvastatin on oxidized LDL (OxLDL) in patients with acute coronary syndromes (ACS)...
  23. ncbi High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial
    Anders G Olsson
    Department of Medicine and Care, Internal Medicine, University of Linkoping, SE 58185 Linkoping, Sweden
    Eur Heart J 26:890-6. 2005
    ..We determined whether plasma lipoproteins at baseline and then at 6 weeks after randomization predicted clinical outcome...
  24. ncbi Statins in acute coronary syndromes: the sooner, the better?
    Gregory G Schwartz
    Am Heart J 149:377-80. 2005
  25. ncbi Early initiation of treatment with statins in acute coronary syndromes
    Anders G Olsson
    Faculty of Health Sciences, University of Linkoping, Sweden
    Ann Med 34:37-41. 2002
    ..The studies highlight the importance of treatment with a statin in the early management of acute coronary syndromes and the need to incorporate this therapeutic strategy in national guidelines and treatment recommendations...
  26. ncbi Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials
    Matthias Briel
    Basel Institute for Clinical Epidemiology, University Hospital Basel, Basel, Switzerland
    JAMA 295:2046-56. 2006
    ..CONCLUSION: Based on available evidence, initiation of statin therapy within 14 days following onset of ACS does not reduce death, MI, or stroke up to 4 months...
  27. ncbi Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study)
    Anders G Olsson
    Faculty of Health Sciences, University of Linkoping, Linkoping, Sweden
    Am J Cardiol 99:632-5. 2007
    ..In conclusion, these results and a greater immediate cardiovascular risk in older patients argue for early, intensive atorvastatin therapy as routine practice after ACS...
  28. ncbi High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study
    Scott Kinlay
    Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, 75 Francis St, Boston, Mass 02115, USA
    Circulation 108:1560-6. 2003
    ..Although statins reduce inflammatory markers in asymptomatic adults or in patients with stable angina, the effect of statins on the markedly heightened inflammation in patients with acute coronary syndromes is unknown...
  29. ncbi Perioperative beta-blockade: a survey of physician attitudes in the department of Veterans Affairs
    Martin J London
    Department of Anesthesia and Perioperative Care, San Francisco Veterans Affairs Medical Center, University of California, San Francisco, CA, USA
    J Cardiothorac Vasc Anesth 18:14-24. 2004
    ....